Drug intelligence / Profile preview

IVMED-93

Development stage: Preclinical
Lead developer: iVeena Delivery Systems

Overview

IVMED-93 is a preclinical drug candidate developed by iVeena Delivery Systems for the treatment of an undisclosed rare orphan disease. iVeena Delivery Systems is a clinical-stage biopharmaceutical company that focuses on developing innovative ophthalmology products, particularly those utilizing sustained-release delivery technologies. While the company's more advanced programs target lysyl oxidase for corneal and refractive conditions, IVMED-93 is in early development, and its specific molecular target, modality, and mechanism of action have not yet been publicly characterized.

Beyond the preview

Go deeper on IVMED-93.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVMED-93.

Explore the full profile